MX2021000459A - Metodo para producir celulas t gamma y delta. - Google Patents
Metodo para producir celulas t gamma y delta.Info
- Publication number
- MX2021000459A MX2021000459A MX2021000459A MX2021000459A MX2021000459A MX 2021000459 A MX2021000459 A MX 2021000459A MX 2021000459 A MX2021000459 A MX 2021000459A MX 2021000459 A MX2021000459 A MX 2021000459A MX 2021000459 A MX2021000459 A MX 2021000459A
- Authority
- MX
- Mexico
- Prior art keywords
- cells
- producing
- pluripotent stem
- induced pluripotent
- stem cells
- Prior art date
Links
- 210000001744 T-lymphocyte Anatomy 0.000 title abstract 3
- 238000004519 manufacturing process Methods 0.000 title abstract 2
- 210000004263 induced pluripotent stem cell Anatomy 0.000 abstract 2
- 210000004027 cell Anatomy 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464411—Immunoglobulin superfamily
- A61K39/464412—CD19 or B4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5443—IL-15
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
- A61K2039/55527—Interleukins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/48—Blood cells, e.g. leukemia or lymphoma
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/05—Inorganic components
- C12N2500/10—Metals; Metal chelators
- C12N2500/20—Transition metals
- C12N2500/24—Iron; Fe chelators; Transferrin
- C12N2500/25—Insulin-transferrin; Insulin-transferrin-selenium
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/38—Vitamins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/125—Stem cell factor [SCF], c-kit ligand [KL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/145—Thrombopoietin [TPO]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/21—Chemokines, e.g. MIP-1, MIP-2, RANTES, MCP, PF-4
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2302—Interleukin-2 (IL-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2315—Interleukin-15 (IL-15)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2321—Interleukin-21 (IL-21)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/26—Flt-3 ligand (CD135L, flk-2 ligand)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/40—Regulators of development
- C12N2501/48—Regulators of apoptosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/599—Cell markers; Cell surface determinants with CD designations not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/70—Enzymes
- C12N2501/72—Transferases (EC 2.)
- C12N2501/727—Kinases (EC 2.7.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- General Engineering & Computer Science (AREA)
- Hematology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
La presente invención proporciona un método para la producción de una célula ?dT a partir de una célula madre pluripotente inducida, en donde la célula madre pluripotente inducida se deriva a partir de una célula diferente de una célula aßT.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2018133727 | 2018-07-13 | ||
JP2019117891 | 2019-06-25 | ||
PCT/JP2019/027697 WO2020013315A1 (ja) | 2018-07-13 | 2019-07-12 | γδT細胞の製造方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2021000459A true MX2021000459A (es) | 2021-06-23 |
Family
ID=69143058
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2021000459A MX2021000459A (es) | 2018-07-13 | 2019-07-12 | Metodo para producir celulas t gamma y delta. |
Country Status (14)
Country | Link |
---|---|
US (1) | US20210130777A1 (es) |
EP (1) | EP3822342A4 (es) |
JP (1) | JP7479635B2 (es) |
KR (1) | KR20210030373A (es) |
CN (1) | CN112513256A (es) |
AU (1) | AU2019302207A1 (es) |
BR (1) | BR112021000437A2 (es) |
CA (1) | CA3106089A1 (es) |
CO (1) | CO2021001064A2 (es) |
IL (1) | IL280041A (es) |
MX (1) | MX2021000459A (es) |
SG (1) | SG11202100260QA (es) |
TW (1) | TW202020145A (es) |
WO (1) | WO2020013315A1 (es) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109337870B (zh) * | 2018-12-24 | 2020-07-03 | 广东暨德康民生物科技有限责任公司 | 人Vγ9Vδ2T细胞扩增方法与培养基 |
IL293564A (en) * | 2019-12-06 | 2022-08-01 | Fate Therapeutics Inc | Enhancement of an effector immune cell, derived from an induced pluripotent stem cell, using small molecules |
CN115885038A (zh) | 2020-06-17 | 2023-03-31 | 国立大学法人京都大学 | 表达嵌合抗原受体的免疫活性细胞 |
JPWO2022168959A1 (es) * | 2021-02-05 | 2022-08-11 | ||
AU2022252997A1 (en) * | 2021-04-07 | 2023-09-28 | Century Therapeutics, Inc. | Compositions and methods for generating gamma-delta t cells from induced pluripotent stem cells |
CN113583955A (zh) * | 2021-08-24 | 2021-11-02 | 羽铂精制生物技术(成都)有限公司 | 一种因子法扩增t细胞的培养基及培养方法 |
AU2022388808A1 (en) * | 2021-11-12 | 2024-06-27 | Janssen Biotech, Inc. | Materials and methods for improved expansion and uses of immune cells |
WO2023194915A1 (en) * | 2022-04-04 | 2023-10-12 | Gammadelta Therapeutics Ltd | Novel gene armoring |
WO2023194911A1 (en) * | 2022-04-04 | 2023-10-12 | Gammadelta Therapeutics Ltd | Cells expressing an anti-mesothelin car |
Family Cites Families (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4937190A (en) | 1987-10-15 | 1990-06-26 | Wisconsin Alumni Research Foundation | Translation enhancer |
NZ522337A (en) | 2000-04-03 | 2004-12-24 | Hemosol Inc | Production of TcR gamma delta T cells |
US9453219B2 (en) | 2003-05-15 | 2016-09-27 | Mello Biotech Taiwan Co., Ltd. | Cosmetic designs and products using intronic RNA |
JPWO2006006720A1 (ja) | 2004-07-13 | 2008-05-01 | 株式会社メディネット | γδT細胞の培養方法、γδT細胞及び治療・予防剤 |
CN101356270B (zh) | 2005-12-13 | 2014-02-12 | 国立大学法人京都大学 | 核重新编程因子 |
US8440461B2 (en) | 2007-03-23 | 2013-05-14 | Wisconsin Alumni Research Foundation | Reprogramming somatic cells using retroviral vectors comprising Oct-4 and Sox2 genes |
WO2008153029A1 (ja) | 2007-06-11 | 2008-12-18 | Takara Bio Inc. | 特異的遺伝子発現方法 |
JP2008307007A (ja) | 2007-06-15 | 2008-12-25 | Bayer Schering Pharma Ag | 出生後のヒト組織由来未分化幹細胞から誘導したヒト多能性幹細胞 |
ES2589122T3 (es) | 2007-08-31 | 2016-11-10 | Whitehead Institute For Biomedical Research | Estimulación de la ruta de la Wnt en la reprogramación de células somáticas |
AU2008297024B2 (en) | 2007-10-31 | 2014-08-28 | Kyoto University | Nuclear reprogramming method |
KR101532442B1 (ko) | 2007-12-10 | 2015-06-29 | 고쿠리츠 다이가쿠 호진 교토 다이가쿠 | 효율적인 핵 초기화 방법 |
US20100330063A1 (en) | 2007-12-17 | 2010-12-30 | Gliamed, Inc. | Stem-like cells, method for de-differentiating mammalian somatic cells into stem-like cells, and method for differentiating stem-like cells |
CN101970664B (zh) | 2008-01-16 | 2013-08-21 | 林希龙 | 使用可诱导的重组核糖核酸因子生成不含肿瘤的类胚胎干细胞的多能性细胞 |
EP2250252A2 (en) | 2008-02-11 | 2010-11-17 | Cambridge Enterprise Limited | Improved reprogramming of mammalian cells, and the cells obtained |
EP2090649A1 (en) | 2008-02-13 | 2009-08-19 | Fondazione Telethon | Method for reprogramming differentiated cells |
WO2009102983A2 (en) | 2008-02-15 | 2009-08-20 | President And Fellows Of Harvard College | Efficient induction of pluripotent stem cells using small molecule compounds |
RU2010139426A (ru) | 2008-03-17 | 2012-04-27 | Зе Скрипс Ресеч Инститьют (Us) | Комбинация химического и генетического подходов к получению индуцированных плюрипотентных стволовых клеток |
WO2009114949A1 (en) | 2008-03-20 | 2009-09-24 | UNIVERSITé LAVAL | Methods for deprogramming somatic cells and uses thereof |
KR20110007607A (ko) | 2008-04-07 | 2011-01-24 | 뉴포텐셜, 인크. | 소분자 조절제의 사용을 통한 다능 유전자의 유도에 의한 세포 재프로그래밍 |
CN101835890B (zh) | 2008-06-27 | 2013-07-24 | 国立大学法人京都大学 | 有效建立诱导的多能干细胞的方法 |
JP4281071B1 (ja) * | 2008-07-10 | 2009-06-17 | 学校法人兵庫医科大学 | Vγ9Vδ2T細胞の増殖剤、活性化Vγ9Vδ2T細胞の製造方法およびこれらの利用 |
AU2009271149A1 (en) | 2008-07-14 | 2010-01-21 | Oklahoma Medical Research Foundation | Production of pluripotent cells through inhibition of Bright/ARID3a function |
WO2010147612A1 (en) | 2009-06-18 | 2010-12-23 | Lixte Biotechnology, Inc. | Methods of modulating cell regulation by inhibiting p53 |
WO2010033920A2 (en) | 2008-09-19 | 2010-03-25 | Whitehead Institute For Biomedical Research | Compositions and methods for enhancing cell reprogramming |
US20120021519A1 (en) | 2008-09-19 | 2012-01-26 | Presidents And Fellows Of Harvard College | Efficient induction of pluripotent stem cells using small molecule compounds |
WO2010042800A1 (en) | 2008-10-10 | 2010-04-15 | Nevada Cancer Institute | Methods of reprogramming somatic cells and methods of use for such cells |
US20110250692A1 (en) | 2008-10-30 | 2011-10-13 | Kyoto University | Method for producing induced pluripotent stem cells |
US20110059526A1 (en) | 2008-11-12 | 2011-03-10 | Nupotential, Inc. | Reprogramming a cell by inducing a pluripotent gene through use of an hdac modulator |
EP2376626A4 (en) | 2008-12-13 | 2012-10-17 | Dna Microarray | MICRO-ENVIRONMENTAL NICHE ASSAY FOR SCREENING OF INDUCED PLURIPOTENT STEM CELLS (CIPS) |
EP2607476B1 (en) | 2009-02-27 | 2015-04-08 | Kyoto University | Novel nuclear reprogramming substance |
US20120122212A1 (en) | 2009-03-06 | 2012-05-17 | Marica Grskovic | Tgf-beta pathway inhibitors for enhancement of cellular reprogramming of human cells |
WO2010111422A2 (en) | 2009-03-25 | 2010-09-30 | The Salk Institute For Biological Studies | Induced pluripotent stem cell generation using two factors and p53 inactivation |
US9340775B2 (en) | 2009-03-25 | 2016-05-17 | The Salk Institute For Biological Studies | Induced pluripotent stem cell produced by transfecting a human neural stem cell with an episomal vector encoding the Oct4 and Nanog proteins |
US8852940B2 (en) | 2009-04-01 | 2014-10-07 | The Regents Of The University Of California | Embryonic stem cell specific microRNAs promote induced pluripotency |
EP2421956A4 (en) | 2009-04-24 | 2013-10-02 | Whitehead Biomedical Inst | COMPOSITIONS AND METHODS FOR OBTAINING OR CULTURING PLURIPOTENTER CELLS |
JP2012528599A (ja) | 2009-06-05 | 2012-11-15 | セルラー ダイナミクス インターナショナル, インコーポレイテッド | リプログラミングt細胞および造血細胞 |
WO2010147395A2 (en) | 2009-06-16 | 2010-12-23 | Korea Research Institute Of Bioscience And Biotechnology | Medium composition comprising neuropeptide y for the generation, maintenance, prologned undifferentiated growth of pluripotent stem cells and method of culturing pluripotent stem cell using the same |
JP6344821B2 (ja) | 2011-11-21 | 2018-06-20 | ユニバーシティ・ヘルス・ネットワーク | 造血前駆体の集団および造血前駆体のための幹細胞を富化する方法 |
AU2014248119B2 (en) * | 2013-04-03 | 2019-06-20 | Memorial Sloan-Kettering Cancer Center | Effective generation of tumor-targeted T-cells derived from pluripotent stem cells |
EP3170895A4 (en) | 2014-07-18 | 2018-07-11 | Kawamoto, Hiroshi | Production method for pluripotent stem cells having antigen-specific t cell receptor gene |
JP2017535284A (ja) | 2014-11-05 | 2017-11-30 | ボード・オブ・リージエンツ,ザ・ユニバーシテイ・オブ・テキサス・システム | 免疫エフェクター細胞の拡大のための遺伝子改変免疫エフェクター細胞及び遺伝子操作細胞 |
JP6736003B2 (ja) | 2014-11-13 | 2020-08-05 | 国立大学法人京都大学 | 多能性幹細胞からt細胞への誘導方法 |
GB201421716D0 (en) | 2014-12-05 | 2015-01-21 | King S College London | Cell expansion procedure |
CA3003145A1 (en) | 2015-10-30 | 2017-05-04 | Gay M. Crooks | Methods of generating t-cells from stem cells and immunotherapeutic methods using the t-cells |
CN109415699A (zh) | 2016-06-23 | 2019-03-01 | 国立大学法人京都大学 | Cd4cd8双阳性t细胞的制备方法 |
EP3572502B1 (en) | 2017-01-20 | 2023-01-11 | Kyoto University | Method for producing cd8alpha +beta + cytotoxic t cells |
US20200017837A1 (en) * | 2017-02-03 | 2020-01-16 | National University Corporation Kobe University | Method For Producing Induced Pluripotent Stem Cells |
US20190359940A1 (en) | 2017-02-07 | 2019-11-28 | Agency For Science, Technology And Research | Methods and kits for generating mimetic innate immune cells from pluripotent stem cells |
JP2018133727A (ja) | 2017-02-16 | 2018-08-23 | 富士通株式会社 | 無線通信システム、無線通信装置、及びビームパターン決定方法 |
JP7109916B2 (ja) | 2017-12-27 | 2022-08-01 | 株式会社ディスコ | 分割装置 |
-
2019
- 2019-07-12 SG SG11202100260QA patent/SG11202100260QA/en unknown
- 2019-07-12 CA CA3106089A patent/CA3106089A1/en active Pending
- 2019-07-12 EP EP19833471.6A patent/EP3822342A4/en active Pending
- 2019-07-12 JP JP2020530276A patent/JP7479635B2/ja active Active
- 2019-07-12 MX MX2021000459A patent/MX2021000459A/es unknown
- 2019-07-12 US US17/259,736 patent/US20210130777A1/en active Pending
- 2019-07-12 BR BR112021000437-8A patent/BR112021000437A2/pt unknown
- 2019-07-12 AU AU2019302207A patent/AU2019302207A1/en active Pending
- 2019-07-12 WO PCT/JP2019/027697 patent/WO2020013315A1/ja unknown
- 2019-07-12 TW TW108124699A patent/TW202020145A/zh unknown
- 2019-07-12 CN CN201980050138.3A patent/CN112513256A/zh active Pending
- 2019-07-12 KR KR1020217002142A patent/KR20210030373A/ko unknown
-
2021
- 2021-01-10 IL IL280041A patent/IL280041A/en unknown
- 2021-01-29 CO CONC2021/0001064A patent/CO2021001064A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
BR112021000437A2 (pt) | 2021-04-06 |
JP7479635B2 (ja) | 2024-05-09 |
SG11202100260QA (en) | 2021-02-25 |
KR20210030373A (ko) | 2021-03-17 |
AU2019302207A1 (en) | 2021-03-04 |
TW202020145A (zh) | 2020-06-01 |
CO2021001064A2 (es) | 2021-02-08 |
WO2020013315A1 (ja) | 2020-01-16 |
EP3822342A1 (en) | 2021-05-19 |
CA3106089A1 (en) | 2020-01-16 |
EP3822342A4 (en) | 2022-08-03 |
CN112513256A (zh) | 2021-03-16 |
IL280041A (en) | 2021-03-01 |
US20210130777A1 (en) | 2021-05-06 |
JPWO2020013315A1 (ja) | 2021-08-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2021000459A (es) | Metodo para producir celulas t gamma y delta. | |
MX2019007020A (es) | Anticuerpos il-11. | |
MX2021006235A (es) | Anticuerpos anti-tigit, anticuerpos anti-pvrig y combinaciones de estos. | |
MX2019007021A (es) | Anticuerpos il-11ra. | |
MX2019011040A (es) | Composiciones y metodos para potenciar la expresion genica. | |
MX2022016566A (es) | Composiciones que comprenden una caseina y metodos para producir las mismas. | |
IL249828A0 (en) | Limbal stem cells of cultured mammals, methods of their creation and uses thereof | |
SG10201810150UA (en) | Compositions and methods for enhanced gene expression in cone cells | |
MX2019014497A (es) | Metodo para producir celula eucariota de adn editado, y kit usado en el mismo. | |
AU2016250905A8 (en) | Generation of muscle-lineage cells from stem cells | |
MX2021012461A (es) | Procesos para preparar y usar un secretoma derivado de células madre mesenquimales. | |
MX2021006564A (es) | Sistemas activos dinamicos acromosomicos. | |
BR112017018885A2 (pt) | método de cultura celular para células-tronco mesenquimais | |
PH12020551031A1 (en) | Modified homoserine dehydrogenase and method for producing homoserine or l-amino acid derived from homoserine using the same | |
MY195583A (en) | Modified Homoserine Dehydrogenase and Method for Producing Homoserine Or L-Amino Acid Derived from Homoserine using the same | |
MX2022000893A (es) | Metodo de obtencion de mitocondrias de celulas y mitocondrias obtenidas. | |
MX2021003654A (es) | Metodo para seleccionar neoepitopes. | |
MX2021000066A (es) | Métodos y composiciones para la preparacion de tagatosa a partir de fructosa. | |
WO2018101663A3 (ko) | 생체 조직 투명화용 조성물 및 이를 이용한 생체 조직 투명화 방법 | |
MX2018003678A (es) | Metodos moleculares de aseguramiento de la calidad para su uso en la secuenciacion. | |
MX2019010492A (es) | Kits y metodos para preparar composiciones de plaquetas con patogeno inactivado. | |
MX2021003180A (es) | Métodos y kits para preparar sangre entera con inactivación de patógenos. | |
MX2019008241A (es) | Un enlazador polipeptídico para preparar anticuerpos multispecíficos. | |
MX2021010417A (es) | Replicas de cafe producidas a partir de componentes individuales. | |
MX2017009180A (es) | Biomateriales de nanocelulosa sintetizada bacterialmente y de fases múltiples, y método para producirlos. |